Onglyza & Kombiglyze XR

What are Onglyza and Kombiglyze XR?

Onglyza and Kombiglyze XR are Type 2 diabetes medications that were approved by the FDA in 2009 and 2010, respectively.  The active ingredient of Onglyza is saxagliptin while Kombiglyze combines saxagliptin with metformin.

These drugs act as a DPP-4 inhibitor.  DPP-4 is an enzyme which breaks down the hormone GLP-1.  After you eat, GLP-1 is released into the bloodstream and triggers the body to make more insulin.  By inhibiting DPP-4, more GLP-1 remains in the blood signaling the pancreas to continue making more insulin after meals.

Onglyza and Kombiglyze XR also reduce the amount of glucagon secreted by the pancreas.  This prevents the liver from creating too much glucose, which is a problem among those suffering from Type 2 diabetes.

What are the problems with Onglyza and Kombiglyze XR?

There are serious side effects that have been associated with the diabetes drugs Onglyza and Kombiglyze XR.  These issues can include Pancreatitis, Pancreatic Cancer, Congestive Heart  Failure, Cardiac Failure and Death.

Because Kombiglyze XR contains Metformin as well as saxagliptin, it brings the risk of lactic acidosis, which results in a buildup of lactic acid in the blood which can result in death.

How can United Law help?

If you or a loved one has been adversely affected by Onglyza or Kombiglyze XR, United Law is here to help.  Patients who have been diagnosed with pancreatic cancer while on these prescription medications have already filed lawsuits against the manufacturer.

Our attorneys are ready to work with you to get you the compensation that you deserve.  Please call us at 888.685.7689 for a free consultation.